… German claims data to compare the effectiveness and safety of newly-initiated apixaban and
VKA therapy in NVAF patients… stroke risk with apixaban in routine practice compared to VKA …

… , dabigatran vs apixaban, and rivaroxaban vs apixaban were performed following … relative
effectiveness and safety of dabigatran vs VKA among the PS-trimmed and PS-matched patient …

… clinical practice could provide a significant platform for the comparative effectiveness and
safety … major bleeding of apixaban with dabigatran in patients with atrial fibrillation. IV indicates …

… Germany has steadily increased and since 2016 exceeded the number of previously preferred
vitamin K antagonists … observable, as dabigatran and apixaban user show a higher stroke …

… vitamin K antagonist (VKA). There is little evidence documenting … A retrospective cohort study
using a German claims … predominant VKA in clinical practice, comparative data for NOACs …

… OR new oral anticoagulants OR novel oral anticoagulants OR dabigatran OR rivaroxaban
OR apixaban OR edoxaban AND vitamin-K antagonists OR warfarin OR coumadin OR …

… (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and
… impact clinical practice and choice of anticoagulants in atrial fibrillation patients. Moreover, …

… demonstrated better efficacy and safety characteristics than … effects of using apixaban instead
of VKA in the German NVAF … in clinical practice with an overall prevalence of around 2% …

… composite DOACs and apixaban (number needed to treat, NNT 101 … in Germany: dabigatran,
rivaroxaban, apixaban and … to decisions in daily clinical practice, several limitations hold …

… standard of care - VKAs - in the routine setting of clinical practice. The results of the meta-…
and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation…